Good analysis. Further to it adding to an already approved treatment - there is two points.
1) OPT302 may still actually have potential single agent efficacy (that could potentially rival Lucentis) ... this would be pretty big news but has a lower probability.
2) It is really not just "adding" to the treatment, it is finishing off the puzzle of VEGF pathway blockade. For those among us that have studied these types of pathways, this also has some big implications to other related treatments.
As above, having clear easy to measure, quick endpoints is a huge plus for ANY trial design across lots of biotechs.
Exciting stuff!
Always DYOR, my insights only.
Cheers,
Sol
Good analysis. Further to it adding to an already approved...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $467.8M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.5¢ | $176.6K | 463.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 121324 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 90033 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |